Carlyle price target lowered to $47 from $50 at BofA
BofA analyst Craig Siegenthaler lowered the firm’s price target on Carlyle (CG) to $47 from $50 and keeps an Underperform ...
Carlyle's profit misses estimates as private equity business weighs
Carlyle Group's distributable fourth-quarter earnings missed market expectations on Tuesday, eclipsing a strong growth in the ...
The Carlyle Group (NASDAQ:CG) Cut to Sell at StockNews.com
The Carlyle Group (NASDAQ:CG – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “hold” ...
Carlyle's Savino Expects IPOs to Increase in 2025
Matt Savino, Carlyle global head of capital markets, expects the IPO market to improve in 2025. He is on "Bloomberg ." ...
Carlyle's profit misses estimates on lower proceeds from asset sales
Carlyle Group's distributable earnings for the fourth quarter missed market expectations on Tuesday, overshadowing a strong ...
Carlyle Group (CG) Receives a Rating Update from a Top Analyst
Bank of America Securities analyst Craig Siegenthaler maintained a Sell rating on Carlyle Group (CG – Research Report) yesterday and set a ...
Carlyle Group Enters Indian Auto Parts Industry With Highway-Roop Platform Buy
(Reuters) - U.S.-based investment firm Carlyle Group has entered India's auto components market by buying a controlling stake ...
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.